[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aswan University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,66,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100650242","testing-two-doses-of-nebulized-ketamine-for-postoperative-sore-throat-100650242",false,"NCT07746115","Testing Two Doses of Nebulized Ketamine for Postoperative Sore Throat","Optimizing Nebulized Ketamine for Postoperative Sore Throat Relief: A Placebo-Controlled Randomized Trial","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Scheduled for elective surgery under general anesthesia requiring endotracheal intubation.\n* Able to provide written informed consent.\n* Willing to comply with all study procedures and follow-up assessments.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to ketamine.\n* Pre-existing sore throat, hoarseness, or significant upper airway pathology.\n* Current upper respiratory tract infection.\n* Anticipated difficult airway or more than one intubation attempt.\n* Surgery involving the upper airway, oral cavity, pharynx, larynx, or maxillofacial region.\n* Severe cardiovascular disease or uncontrolled hypertension.\n* Severe respiratory disease.\n* Pregnancy or breastfeeding.\n* History of psychiatric illness or psychosis.\n* Chronic opioid use or regular use of analgesic or anti-inflammatory medications.\n* Inability to communicate postoperative symptoms or complete study assessments.","ALL","18 Years","65 Years",{"count":20,"type":21},195,"ESTIMATED","INTERVENTIONAL",[24],"NA","Postoperative sore throat (POST) is one of the most common complications following general anesthesia with endotracheal intubation, affecting patient comfort, delaying recovery, and reducing overall satisfaction with perioperative care. Although POST is usually self-limiting, its high incidence makes it an important target for preventive interventions.\n\nNebulized ketamine has emerged as a promising non-invasive strategy for reducing POST because of its local analgesic and anti-inflammatory effects mediated through N-methyl-D-aspartate (NMDA) receptor antagonism. Previous randomized trials and systematic reviews have demonstrated that nebulized ketamine can reduce both the incidence and severity of POST compared with placebo. However, most published studies have evaluated a single 50-mg dose, and the minimum effective dose remains uncertain.\n\nThis prospective, randomized, placebo-controlled, double-blind clinical trial aims to compare the efficacy and safety of two preoperative doses of nebulized ketamine (25 mg and 50 mg) with placebo in adult patients undergoing elective surgery under general anesthesia with endotracheal intubation. Participants aged 18-65 years with American Society of Anesthesiologists (ASA) physical status I or II will be randomly assigned in a 1:1:1 ratio to receive nebulized ketamine 25 mg, nebulized ketamine 50 mg, or nebulized normal saline 15 minutes before induction of anesthesia.\n\nThe primary outcome is the incidence of postoperative sore throat assessed at 2, 4, 6, 12, and 24 hours after surgery using a standardized four-point grading scale. Secondary outcomes include the severity of POST, postoperative pain intensity measured using the Visual Analog Scale (VAS), patient satisfaction, need for rescue analgesia, sedation assessed using the Ramsay Sedation Scale, and the incidence of adverse effects, including nausea, dizziness, and hallucinations.\n\nThe study hypothesizes that a lower dose of nebulized ketamine (25 mg) will provide comparable protection against postoperative sore throat to the conventional 50-mg dose while minimizing dose-related adverse effects. Identifying the minimum effective dose may improve the safety profile, optimize perioperative patient comfort, and support evidence-based recommendations for preventing postoperative sore throat after endotracheal intubation.",[27],"Postoperative Sore Throat","NOT_YET_RECRUITING","2026-08-04",{"date":31,"type":32},"2026-08-05","ACTUAL",{"date":34,"type":21},"2026-08-15",{"date":36,"type":21},"2027-03-01",{"name":38,"class":39},"Aswan University Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100557377","femoral-nerve-block-periarticular-nerve-group-peng-block-and-preoperative-iv-fentanyl-100557377","NCT06537323","Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl","Comparative Analysis of Educational Interventions and Anesthetic Techniques for Enhanced Spinal Anesthesia Quality in Fractured Neck of Femur: Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl","Inclusion Criteria:\n\n* The included patient should be between 55 to 69 years\n\nExclusion Criteria:\n\n* known allergies to local anesthetics",true,"55 Years","69 Years",{"count":51,"type":21},210,[24],"The pericapsular nerve group block is a regional anesthetic technique described in 2018, developed primarily in total hip arthroplasties for postoperative analgesia with motor sparing benefits. The block is thought to provide more complete analgesia to the hip by depositing local anesthetic within the myofascial plane of the psoas muscle and superior pubic ramus. The indications for total hip arthroplasties often include degenerative hip disease and traumatic hip fractures. These indications for surgery are relatively common in the elderly population and are associated with significant morbidity and mortality.",[55],"Postoperative Pain","RECRUITING","2025-03-11",{"date":59,"type":32},"2025-03-13",{"date":61,"type":32},"2024-06-01",{"date":63,"type":21},"2025-03-10",{"name":38,"class":39},1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100576618","phase-1-effects-of-neostigmine-dose-on-diaphragmatic-dynamics-100576618","NCT06787638","Effects of Neostigmine-dose on Diaphragmatic Dynamics","Diaphragmatic Dynamics in Laparoscopic Cholecystectomy: Comparing Neuromuscular Blocker Reversal Strategies-A Randomized Trial","DTF\u002FDE\u002FAChE","Inclusion Criteria:\n\n* Adults scheduled for elective laparoscopic cholecystectomy.\n* Age: \\\u003C or = 18 years.\n* Both genders.\n* American Society Of Anesthiologists (ASA) I\u002FII patients.\n* BMI \\\u003C35\n\nExclusion Criteria:\n\n* Pre-existing diaphragmatic or respiratory disorders.\n* ASA III\u002FIV\n* BMI \\>35\n* Chronic opioid use or abuse\n* Pregnancy or breastfeeding","75 Years",{"count":76,"type":21},50,[78],"PHASE1","The goal of this Randomized Clinical Trial is to compare the postoperative diaphragmatic excursion between patients receiving half-dose neostigmine (0.04 mg\u002Fkg) and those receiving full-dose neostigmine (0.08 mg\u002Fkg) for neuromuscular blockade reversal.\n\nThe main questions it aims to answer are:\n\n* Does half-dose neostigmine result in similar postoperative diaphragmatic excursion compared to full-dose neostigmine?\n* Does half-dose neostigmine result in similar diaphragmatic thickening fraction compared to full-dose neostigmine? Researchers will compare patients receiving half-dose neostigmine to those receiving full-dose neostigmine to see if there are differences in postoperative diaphragmatic function, respiratory complications, and recovery.\n\nParticipants will:\n\n* Undergo elective laparoscopic cholecystectomy.\n* Receive either half-dose or full-dose neostigmine for neuromuscular blockade reversal.",[81],"Diaphragm Ultrasound",[83,84],"Diaphragmatic Thickening Fraction","Diaphragmatic Excursion","2025-01-16",{"date":87,"type":32},"2025-01-22",{"date":89,"type":21},"2025-01-25",{"date":91,"type":21},"2026-04",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":100,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":65},"100560933","phase-2-evaluation-of-efficacy-of-botulinum-toxin-a-plus-oral-tadalafil-5-mg-in-diabetic-men-with-erectile-dysfunction-100560933","NCT06583590","Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction","Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction Not Responding to Approved Oral or Intracorporeal Vasoactive Treatments.","Inclusion Criteria:\n\n* Adult controlled diabetic married men who proved to be vasculogenic ED by Penile Duplex.\n* Men who had shown an insufficient response for at least 3 months to the registered PDE5-Is at the highest approved dose, either on-demand or daily, or to PGE1 ICIs.\n* Severe erectile dysfunction (erection hardness score ≤ E3 after intracavernosal injection of PGE-1).\n\nExclusion Criteria:\n\n* Men who had cardiovascular disease interfering with sexual activity.\n* Men with history of an unstable psychiatric conditions\n* Presence of penile anatomical abnormalities that would significantly impair erectile function.\n* History of spinal or pelvic radical surgery.","MALE","21 Years",{"count":103,"type":21},32,[105,106],"PHASE2","PHASE3","Study is aiming to evaluate safety, efficacy and durability of intracavernosal injection (ICI) of Botulinum toxin A plus oral tadalafil in controlled diabetic men with refractory Erectile Dysfunction.",[109],"Erectile Dysfunction With Diabetes Mellitus","2024-11-30",{"date":112,"type":32},"2024-12-03",{"date":114,"type":32},"2024-08-01",{"date":116,"type":21},"2025-12-01",{"name":38,"class":39},""]